AstraZeneca Educational Webinar Series

Presented by AADE in Association with AstraZeneca-US Medical Affairs, CVMD Division

This educational webinar series is designed to provide the most up-to-date, cutting edge information in diabetes. Each webinar will be presented live and recorded. Archived presentations will be posted on this page for up to 40 days after the live broadcast, so don't miss out!

This webinar series is educational in nature and contains no promotional or product information. CE credit is not available for this activity.






Webinar Schedule:

April 25: Evaluating Cardiovascular Safety of T2D Medicines

June 6: GLP-1 Physiology and Overview of Approved GLP-1 Receptor Agonists

July 11: SGLT-2

September 12: Combination Therapy

October 17: Cardiovascular/Metabolic Disease




Evaluating Cardiovascular Safety of T2D Medicines


Presented by Susan Thomas, MD, and Curtis Triplitt, PharmD, CDE, this webinar highlights the risk of cardiovascular disease in patients with diabetes and findings which have led to the FDA Guidance for evaluating CV safety of medicines used to treat T2D. It also looks at Cardiovascular Outcome Trial (CVOT) designs, statistical considerations and implications for interpretation, concluding with top-line results from completed CVOTs to date.

Upon completion of this activity, participants will be able to:

  1. Discuss history and regulatory guidance for evaluating cardiovascular safety of newer T2D therapies
  2. Review considerations and potential implications of cardiovascular outcome trial designs
  3. Review top-line data from completed cardiovascular outcomes trials

Originally presented on April 25, 2018





Coming Soon: GLP-1 Physiology and Overview of Approved GLP-1 Receptor Agonists

Presented by James Ruggles, PhD, and Curtis Triplitt, PharmD, CDE, this webinar will review the key hormones for glucose homeostasis and then focus on the incretin hormone GLP-1. The actions of GLP-1 will be covered in both normal physiology and the pathophysiology of type 2 diabetes. Finally, there will be an overview of key clinical and safety data of approved GLP-1 receptor agonists.

Upon completion of this activity, participants will be able to:

  1. Provide an overall understanding of the glucose-dependent actions of GLP-1 and how GLP-1 receptor agonists share these actions.
  2. Educate on intermittent and long-acting GLP-1 receptor agonists and how these agents differ in actions.
  3. Provide an overview of key clinical and safety data for the class.